NEW YORK (GenomeWeb) – Exosome Diagnostics and Chesapeake Urology announced today that they have initiated an evidence development study designed to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore (EPI) prostate cancer test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.